Skip to Content

WCLC2020: Pembrolizumab plus chemotherapy provided durable clinical benefit in patients with metastatic squamous NSCLC

In this MEDtalk Martin Reck give his perspective of KEYNOTE-407 which revealed that combining pembrolizumab with chemo-therapy in patients with previously untreated metastatic squamous NSCLC improved OS, PFS, and PFS-2, increased ORR, and longer duration of respons than placebo plus chemotherapy. The data support the combination of pembrolizumab and chemotherapy as a first-line treat-ment for metastatic squamous NSCLC in patients with PD-L1‒positive and PD-L1‒negative tumors.

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top